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ABSTRACT: Self-emulsifying drug-delivery systems (SEDDS) have been extensively shown to increase oral absorption of
solvation-limited compounds. However, there has been little clinical and commercial use of these formulations, in large part because
the demonstrated advantages of SEDDS have been outweighed by our inability to precisely predict drug absorption from SEDDS
using current in vitro assays. To overcome this limitation and increase the biological relevancy of in vitro assays, an absorption
function can be incorporated using biomimetic membranes. However, the effects that SEDDS have on the integrity of a biomimetic
membrane are not known. In this study, a quartz crystal microbalance with dissipation monitoring and total internal reflection
fluorescence microscopy were employed as complementary methods to in vitro lipolysis-permeation assays to characterize the
interaction of various actively digested SEDDS with a liquescent artificial membrane comprising lecithin in dodecane (LiDo).
Observations from surface analysis showed that interactions between the digesting SEDDS and LiDo membrane coincided with
inflection points in the digestion profiles. Importantly, no indications of membrane damage could be observed, which was supported
by flux profiles of the lipophilic model drug felodipine (FEL) and impermeable marker Lucifer yellow on the basal side of the
membrane. There was a correlation between the digestion kinetics of the SEDDS and the flux of FEL, but no clear correlation
between solubilization and absorption profiles. Membrane interactions were dependent on the composition of lipids within each
SEDDS, with the more digestible lipids leading to more pronounced interactions, but in all cases, the integrity of the membrane was
maintained. These insights demonstrate that LiDo membranes are compatible with in vitro lipolysis assays for improving predictions
of drug absorption from lipid-based formulations.
■ INTRODUCTION
Many pharmaceutical compounds now being developed suffer
from either poor aqueous solubility, high lipophilicity, or both.
For these water-insoluble but cell-permeable compounds, lipid-
based formulation can be an effective method for achieving a
high absorption while at the same time minimizing absorptive
variability between fasted and fed states when administered
orally.1,2 Self-emulsifying drug-delivery systems (SEDDS) are a
class of lipid-based formulations in which mixtures of lipids,
non-ionic surfactants, and sometimes co-solvents or co-
surfactants form a pre-emulsion concentrate.3 When this
preconcentrate is dispersed in intestinal fluid, it spontaneously
forms a fine emulsion.4 The emulsion droplets act as a high-
solubility reservoir for the drug, preventing precipitation and
conveying the drug to the site of absorption. These actions,
together with a rapid equilibrium between the colloidal lipid
phase and the continuous aqueous phase from the large
interfacial area, prevent the absorption rate from being
hindered by the dissolution rate. Thus, SEDDS frequently
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shows improved oral bioavailability over crystalline, lipid-free
formulations for solvation-limited compounds.5−13
While facile to assemble, developing SEDDS and translating
this knowledge into useful clinical and commercial products
has been hindered by a lack of in vitro assays that adequately
predict the relative performance of different compositions.1,14
The most typically performed test is the in vitro lipolysis assay,
in which drug release and digestion kinetics are followed.15
However, because of enzymatic lipolysis, the lipids that make
up a SEDDS undergo significant transformation after
dispersion, as tri- and diglycerides are digested and
monoglycerides and fatty acids are absorbed. Alteration of
the lipid components affects the colloidal structure of the
formulation,16 and thus solubility and partitioning of its cargo.
A key limitation of the in vitro lipolysis assay is the lack of an
absorption step, because absorption of the drug compound is
the end-goal of an oral drug-delivery system. For non-colloidal
systems, drug release is more easily determined and can often
be used to predict the intestinal absorption in vivo; however,
drug release from colloidal systems such as SEDDS is
notoriously challenging to measure, thus leading to poor
predictions when absorption is not accounted for in vitro.1
To overcome these limitations, significant efforts have been
made to develop new in vitro lipolysis methods that include an
absorption step, using cellular monolayers or biomimetic
membranes through which the drug can permeate and be
assessed after fluxing through this barrier.17−20 Keemink et al.
demonstrated a significantly improved correlation between in
vitro absorption and in vivo plasma concentration for the
model drug fenofibrate when absorption was assessed using an
in vitro lipolysis-permeation assay with Caco-2 cell monolayers
(in contrast to earlier lipolysis assays without an absorption
step).17 A similar result was demonstrated in the recent study
by Klitgaard et al., which showed improved correlations with in
vivo absorption for the model drug cinnarizine when assayed in
a lipolysis-permeation setup using a biomimetic membrane.20
Despite the promise of in vitro lipolysis-permeation assays, it
is still unclear whether the biomimetic membrane remains
intact under lipase-mediated digestion. In a previous study,
interactions between different SEDDS and a biomimetic
membrane were suspected during enzymatic lipolysis because
flux of the highly permeable model drug fenofibrate increased
after 30 min of digestion, which suggests that the membrane
did not maintain full integrity.18 The artificial membrane
employed, lecithin-in-dodecane (LiDo), was an analogue of a
well-known commercial product (GIT-0). These products
comprise 20% (wt/vol) soy-derived phospholipids in n-
dodecane, forming a biosimilar membrane when supported
by a porous substrate of hydrophobic polyvinylidene difluoride
(PVDF).18,21 The functional properties of this particular
membrane model have, to our knowledge, only been
previously described in terms of permeability coefficients,22
which means that physical properties and structure when
exposed to conditions simulating the dynamic digestion
environment of the small intestine remain unknown.
In the present study, we have therefore coupled formulation-
dependent drug flux investigations with a quartz crystal
microbalance with dissipation (QCM-D) monitoring and
specialized fluorescence microscopy techniques to elucidate
the effect of SEDDS digestion on membrane structure and
integrity. QCM-D can be used to probe the mechanical
properties (including mass, density, and viscoelasticity) of a
thin film applied to a substrate.23,24 Fluorescence microscopy
techniques such as total internal reflection fluorescence
microscopy (TIRF-M) and fluorescence recovery after
bleaching (FRAP) can be used to selectively probe a confined
narrow plane of adsorbed membranes (Δz 100−300 nm) to
assess membrane integrity and structure.25−27 These analytical
techniques are widely used to study dynamic interactions on
phospholipid bilayers,28−30 and were, therefore, selected, in
combination with bulk lipolysis-permeation assays, to serve as
a novel approach for assessing the effect of SEDDS dispersion
and digestion on biomimetic membrane interactions. The
insights derived from this study have important implications
for the use of newly developed in vitro lipolysis-permeation
assays for predicting drug absorption when formulated with
lipid-based delivery systems.
■ EXPERIMENTAL SECTION
Materials. Acetonitrile (≥99.9%), bovine serum albumin (BSA),
CARBITOL (diethylene glycol monoethyl ether), dimethyl sulfoxide
(DMSO, ≥ 99.9%), D-α-tocopherol polyethylene glycol succinate
(TPGS), hexadecane (anhydrous, 95%), Kolliphor RH40 (macro-
golglycerol hydroxystearate), methanol (99.9%), olive oil, porcine
lipase Type II, Tris-maleate, Tween 85, and warfarin were purchased
from Merck (Darmstadt, Germany). Felodipine (FEL) was kindly
donated by AstraZeneca (Mölndal, Sweden). MIGLYOL 812 N was
kindly donated by IOI Oleo (Wittenberge, Germany). “FaSSIF/
FeSSIF/FaSSGF” (simulated intestinal fluid) powders were purchased
from Biorelevant.com (Croydon, UK). Lucifer yellow (LY) CH
dilithium salt was obtained from Biotium (Fremont, CA, USA).
Lecithin 20% Soy PC extract and 1,2-dioleoyl-sn-glycero-3-phosphoe-
thanolamine-N-(lissamine rhodamine B sulfonyl) were obtained from
Avanti Polar Lipids (Alabaster, AL, USA). N-dodecane (≥99%) was
obtained from Alfa Aesar (Lancashire, UK). Ethanol (99.5%,
denatured with 0.4% isopropyl alcohol) was obtained from Solveco
(Rosersberg, Sweden). All water used was of grade I from a Milli-Q
water purification system (Merck).
Preparation of the Biomimetic Membrane Solution. The
biomimetic membrane solution, LiDo, was prepared by dissolving 2 g
Avanti’s Lecithin 20% Soy PC in a 1.5 vol % solution of ethanol in n-
dodecane. The lecithin was weighed, transferred to a volumetric flask,
and solvent was added to make a final solution of 10 mL. The solution
was shaken, transferred to a glass vial, and centrifuged (2690g, 15 min,
20 °C) to remove the insoluble material. The supernatant was
separated into 1 mL aliquots, capped with nitrogen, and stored in a
freezer at −18 °C until use. Frozen LiDo aliquots were thawed at
room temperature overnight prior to use.
Preparation and Characterization of Drug-Delivery Sys-
tems. FEL was selected as a model drug in this work based on its
physicochemical properties. It is well studied, and represents a
suitable candidate for formulation in SEDDS on the basis of high
lipophilicity, low melting point, limited solubility in water, but high
permeability. The innate fluorescence of FEL allows it to be studied
label-free in fluorescence microscopy. Formulation excipients and
composition (Table 1) were chosen based on their previous use in
several publications, both in vivo and similar systems in vitro.17,18,31
The excipients are commonly used in the field of lipid-based oral drug
delivery. The formulations are representative of different classes of
SEDDS but share key similarities that allow for direct comparisons to
be made between each formulation. SEDDS were prepared as
previously described.18 In short, excipients (37 °C) were weighed into
20 mL glass vials in the proportions described in Table 1, capped with
nitrogen, vortexed, and shaken overnight at 400 rpm (37 °C). The
blank SEDDS were then loaded with FEL (22 mg/g) by mixing and
shaking overnight or until complete dissolution.
An estimate of the solubility of FEL in the formulations was
required in order to select an appropriate dose, where FEL was fully
soluble. Previous studies have shown that the solubility of a drug in
the formulations can be well estimated from the solubility of the drug
in each individual component.32,33 Thus, the solubility of FEL in each
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of the SEDDS components was determined to estimate saturation
levels in SEDDS. Solubility of FEL in the F3 SEDDS was
experimentally determined to verify this principle in the context of
this work.
Equilibrium solubility of FEL in the SEDDS components was
determined by adding an excess of FEL (>200 mg/g) to 1.5 mL
Eppendorf centrifuge tubes containing solvent (olive oil, Kolliphor
RH40, Tween 85, or MIGLYOL 812 N) or SEDDS F3 (control
formulation). The mixture was dispersed thoroughly by vortexing,
followed by equilibrating under shaking (400 rpm, 37 °C) for 65 h
before sampling. The samples were centrifuged (21,000g, 15 min, 37
°C) and supernatants were diluted 10× (wt/wt) in a 2:2:1 (vol/vol)
solution of acetonitrile, methanol, and sodium acetate buffer (25 mM,
pH 5.0), followed by further shaking (400 rpm, 37 °C) for 4 h to fully
equilibrate the mixture, an additional 10-fold dilution (vol/vol), and
centrifugation. The supernatants of the olive oil and MIGLYOL 812
N samples were transferred to HPLC vials for quantification. Samples
from Kolliphor RH40, Tween 85, and the F3 SEDDS were subjected
to a third dilution round (10×) and centrifugation step before HPLC
analysis due to expected high concentrations. The solubility (S) of
FEL in each SEDDS was calculated according to eq 1, as previously
described.32,33
S W SLBF e e∑= (1)
where S is given by the sum of the mass fractions (We) of pure solvent
multiplied by the equilibrium solubility of the compound in the
solvent (Se).
Bulk Lipolysis-Permeation Studies. Generally, all experiments
were initiated by dispersing 2.8% (wt/vol) SEDDS in fasted state
simulated intestinal fluid (FaSSIF), followed by 10 min stirring to
generate the emulsified SEDDS. This concentration was selected
based on the previous studies involving these formulations.17,18,31 The
concentration is representative of a realistic scenario in which the
loaded formulation is administered to a patient, that is, the amount of
formulation required to fill a large capsule and dispersed in a volume
corresponding to the fluid volume in the small intestine after intake of
a glass of water.34 FaSSIF was prepared by dissolving “FaSSIF/
FeSSIF/FaSSGF” powder (2.24 g/L) in lipolysis buffer (2/200 mM
Tris-maleate, 150 mM NaCl, 1.4 mM CaCl2). After 10 min, lipolysis
was initiated by addition of porcine lipase extract, reducing SEDDS
concentration to 2.5% wt/vol. The extract was prepared by dispersing
lipase in cold lipolysis buffer (4 °C, 46 mg/mL), followed by
centrifugation (2690g, 15 min, 5 °C) and extraction of the
supernatant to obtain an extract with an enzymatic activity of 1000
TBU/mL. The final activity of the lipase was 100 TBU/mL in the
digestion chamber.
In the bulk lipolysis-permeation experimentsfurther referred to
as in vitro lipolysis-permeation (IVLP)custom polycarbonate filter
holders were used together with commercially available polystyrene 6-
well plates (Corning, USA). PVDF filters (pore size 0.4 μm, porosity
0.7, thickness 110−140 μm, Immobilon-P, Merck Millipore) were
mounted in the holders and then impregnated with LiDo (16 μL/
cm2) immediately prior to the experiment. The holders were then
transferred into the plate wells and 2 mL of receiver buffer was added
to each well. The receiver buffer consisted of phosphate buffered
saline (PBS, 10 mM, pH 7.40) supplemented with TPGS (0.2% wt/
vol). SEDDS were dispersed in high buffer capacity FaSSIF (200 mM
lipolysis buffer, 2 mM sodium taurocholate and 0.75 mM lecithin),
supplemented with 10 μM LY. The high buffer capacity was set to
prevent the pH from dropping more than 0.2 pH units during
lipolysis, while LY permeation was monitored to verify membrane
integrity.18,35 For all formulations, an initial dispersion was performed
by weighing the emulsion preconcentrate into a 15 mL glass vial,
followed by dispensing FaSSIF and LY from a 10 mM DMSO stock
solution. The mixture was vortexed until no preconcentrate was
visible on the glass surface and then transferred to the prepared filter
holders (1.5 mL per holder). The plate was placed in an incubating
orbital shaker at 37 °C and stirred for 10 min at 450 rpm. The donor
media remaining in the glass vial was immediately sampled and
filtered through a 0.1 μm nylon syringe-filter to remove precipitated
material and larger lipid droplets. Due to the poor dispersibility of F1
formulation, two additional dispersion methods were explored. The
first method was directly adding the preconcentrate to the insert
containing FaSSIF with a pipet. The second method generated
dispersion via high shear using a T18 ULTRA-TURRAX (IKA,
Germany) rotor-stator mixer at 8000 rpm for 2 min immediately prior
to transfer to the inserts.
After 10 min shaking, lipolysis was initiated by the addition of 165
μL of porcine lipase extract. Samples (200 μL) were taken from the
receiver well every 5 min for 20 min, then every 10 min until 60 min
of lipolysis had passed. The sampled volume was replaced by fresh
receiver buffer following every sampling. At the end of the experiment,
samples were taken from the donor media and syringe-filtered. The
membrane-supporting filters were subsequently removed from the
holders and dried for 3 h at 70 °C. The dried filters were then
shredded and equilibrated in 5 mL acetonitrile for 24 h in an orbital
shaker at 37 °C with shaking at 400 rpm to extract FEL prior to
sampling of the extract. Receiver samples were analyzed using a Spark
plate reader (Tecan, Austria) to quantify LY by fluorescence
measurement and by HPLC−UV to quantify FEL. Donor and
membrane samples were diluted 100× and 10×, respectively, in
acetonitrile/water (8:2) and centrifuged (10 min, 21,000g) prior to
HPLC−UV analysis.
The procedure outlined above was also performed at ambient room
temperature (∼22 °C) and without stirring to determine performance
under those conditions. In these experiments, the receiver
concentrations were expected to be low enough to require measuring
by mass spectrometry (MS) instead of UV absorbance, and use of
surfactants in MS can reduce signal intensity by ion suppression.36 For
this reason, the receiver buffer was composed of PBS supplemented
with BSA (4 wt %), which has an effect similar to TPGS in that it
increases the effective receiver volume by binding to the permeated
solute, but it is more easily purged from a solution due to its low
solubility in organic solvents. To precipitate the BSA after sample
collection, the samples were diluted 3× with cold acetonitrile and
centrifuged (21,000g, 15 min, 4 °C) prior to analysis of FEL via LC−
MS.37
Solubilized FEL and Digestion Kinetics during In Vitro
Lipolysis. Due to the restricted volume in the filter holders,
supplementary bulk lipolysis experimentsfurther referred to as in
vitro lipolysis (IVL) experimentswere carried out to better capture
the dynamics of the aqueous drug concentrations in the donor
compartment, as well as capture lipolysis kinetics. In these
experiments, 1.14 g of SEDDS was weighed in a jacketed glass vessel
and heated to 37 °C in a water bath prior to the addition of 40 mL of
low buffer capacity FaSSIF (2 mM). The SEDDS was dispersed by
Table 1. Compositions of Drug-Delivery Systems and
















F1 (MCT) I 100
F2
(s + MCT)
IIIA 40 40 20
F3
(s + LCT)
IIIA 40 40 20
F4 (s) IV 67 33
C/D 8:0, 10:0 16:0,
18:1−2
HLB 11 14−16
aAbbreviations: drug-delivery system types including surfactants (s),
medium-chain triglycerides (MCT), or long-chain triglycerides
(LCT). LCFS = lipid formulation classification system.3 C/D =
number of carbons (C) and unsaturations (D) in the acyl chains of
the respective digestible lipids comprising the formulation. HLB =
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overhead stirring at 400 rpm. After 10 min of dispersion, 4.44 mL of
porcine lipase extract was added to commence lipolysis. During
lipolysis, pH was kept at 6.5 via autotitration (Pharm Titrando 800,
Metrohm, Switzerland) of 0.2 M sodium hydroxide solution. Samples
were taken every 3 min of dispersion and every 5 min of lipolysis until
30 min, then every 10 min until 60 min of lipolysis. After sample
collection, 5 μL/mL of lipase inhibitor (0.5 M 4-bromophenol
boronic acid in methanol) was immediately added to prevent further
lipolysis, and the samples were then centrifuged (21,000g, 3−5 min,
37 °C) to separate precipitated FEL from the aqueous phase. The
supernatants were diluted 100× in acetonitrile prior to analysis with
HPLC−UV to quantify aqueous FEL concentrations. At the end of
the experiment, NaOH solution was rapidly titrated to increase the
pH to nine in order to account for unionized fatty acids and adjust
calculation of the extent of digestion.38 A blank FaSSIF (no
formulation) lipolysis was conducted side-by-side as reference to
account for the buffer capacity and digestion of FaSSIF components.
The amount of liberated ionized fatty acids (ni) was then calculated
by multiplying the titrated volume by the titrant concentration. Total
amounts of liberated fatty acids (ntot) were calculated by summing
total ni from pH-stat titration (pH 6.5) with total ni from titration of
pH 6.5−9 at the end of the experiment, and finally subtracting the
corresponding ni values from the reference experiments (no SEDDS),

















ntot as a function of time (t) during pH-stat titration was then










pH stat6.5 tot= *
‐
‐ (3)
Extent of digestion was then calculated as a fraction of ntot by the
theoretical maximum of fatty acid molecules that could be released
during digestion. This maximum was estimated by doubling the molar
amount of triglycerides added to the reaction vessel on the
assumption that monoglycerides would not be digested within the
experimental timeframe due to stereoselectivity of the lipase.39
Quantification of Analytes in Lipolysis-Permeation and
Lipolysis Experiments. LY was quantified using a Spark plate reader
(Tecan, Austria), set to detection of fluorescence at 428 and 536 nm
wavelength for excitation and emission, respectively. FEL was
analyzed using a UV-DAD coupled 1290 Infinity HPLC (Agilent
Technologies, USA) with a 4.6 × 100 mm ZORBAX Eclipse XDB-
C18 column (Agilent Technologies, USA) kept at 40 °C (injection
volume 20 μL). The mobile phase consisted of water and acetonitrile
(2:8 vol/vol) with isocratic flow (1 mL/min). UV absorbance was
monitored at a wavelength of 262 and 360 nm. The retention time
was 1.84 min. Sample preparation consisted of 100× dilution in PBS
with 0.2% TPGS and a centrifugation step (21,000g, 15 min, 25 °C)
to purify the matrix.
UPLC-MS analysis was performed using a Xevo TQ MS coupled
Acquity UPLC system (Waters, USA) with a BEH C18 column (2.1
× 50 mm, 1.7 μm, Waters). The mobile phase consisted of 5%
acetonitrile and 0.1% formic acid in water (solvent A), and 0.1%
formic acid in acetonitrile (solvent B). Gradient elution at a constant
flow rate of 0.5 mL/min was used. Mobile phase A was decreased
linearly (95−0%) from 0.4 to 1.3 min, followed by a constant flow for
0.30 min, and then a linear increase back to 95% A at 1.6 min until the
end of the run (2 min, injection volume 10 μL). The column oven
and autosampler tray temperature were set at 60 and 10 °C
respectively.
The mass spectrometer was operated in positive electrospray mode
for FEL and warfarin (internal standard of the analytics). The
retention times of these compounds were 1.54 and 1.42 min,
respectively. Precursor-product ion pairs followed were m/z 384 →
278 (cone voltage 5 and collision energy 35 V) for FEL, and m/z 309
→ 163 (cone voltage 22 and collision energy 14 V) for warfarin. Data
acquisition and peak integration were performed with MassLynx
software (Waters, USA). Sample preparation consisted of dilution 1:2
in ice-cold warfarin in acetonitrile solution (50 nM), and a
centrifugation step (4 °C, 20,000g for 20 min) to precipitate albumin
from the matrix.
Each analysis was performed using minimum eight calibrator
samples and four quality controls, in triplicate from different stock
solutions. Calibration was performed using first- or second-order
weighted linear regression according to best fit. Residual plots were
used to detect systematic error from the regression model. A
regression coefficient (R2) > 0.995 was required and the calculated
concentrations from the controls were not allowed to deviate more
than 10% from the expected concentration (15% for the lowest
concentration). Unknown samples with responses outside the
calibrated region were not quantified.
Preparation of PVDF Substrates for QCM-D and Microscopy
Experiments. Planar substrates with porous PVDF thin films were
prepared based on the protocol developed by Mullen & Euler.40
Briefly, PVDF (4% wt/vol) was dissolved in a 9:1 solution of acetone
and N,N-dimethylformamide by sonicating for 3 h at 40 °C. The
PVDF solution was then applied to a dried and nitrogen purged silica
substrate (QCM-D crystal or glass) by spin coating. A 100 μL PVDF
solution aliquot was placed on the sample and allowed to spread by
spin coating at 3000 rpm for 60 s. The substrate was dried at 60 °C
for 1 min. The nanostructure of the PVDF coating was investigated
with scanning electron microscopy (SEM) (JEOL JSM-7800F Prime)
by imaging at an accelerating voltage of 1 kV.
QCM-D Studies. QCM-D measurements were performed on
silicon dioxide QSX 303 QCM-D sensors, coated with a PVDF thin
film, and mounted in a Q-Sense E4 system (Biolin Scientific AB,
Sweden). Sensor chambers were maintained at 37 ± 0.1 °C for the
duration of the experiments and the third, fifth, and seventh
harmonics were recorded simultaneously to observe changes in
frequency ( f) and dissipation (D). The sensors were first flushed with
ethanol in n-dodecane solution at a flow rate of 50 μL/min for 5 min
(or until frequency and dissipation stabilized). Membrane formation
was monitored for ∼10−15 min by incubating the sensor chamber
with LiDo solution at continuous flow. The adsorbed membrane was
then exposed to each emulsified SEDDS in FaSSIF medium for 5 min
prior to the addition of porcine lipase to simulate digesting conditions
for 60 min, allowing the influence of the emulsion structure and lipid
digestion on membrane integrity to be monitored. For this
monitoring, a closed-loop lipolysis QCM-D experimental setup was
used to enable continuous flow of the digestion medium over the
supported lipid membrane (Figure 1). Hence, lipolysis media (5 mL)
simulating intestinal digestion conditions (equivalent to those during
Figure 1. Schematic overview (not to scale) of the QCM-D
experimental setup for monitoring SEDDS interactions with adsorbed
LiDo membranes during lipolysis. Phospholipid multilayers are here
illustrated as the monolayers for visual clarity. A peristaltic pump
drives a flow from the reaction vessel (reservoir) to the temperature
controlled QCM-D sensor chamber in which interaction with a
PVDF-treated sensor chip coated with the LiDo solution was
recorded. The outflow from the sensor returns to the reaction vessel,




Langmuir 2021, 37, 10200−10213
10203
in vitro lipolysis studies) were cycled through the sensor chambers.
The flow rate was set to 50 μL/min for the entirety of the experiment.
Lateral Membrane Diffusivity Using Fluorescent Recovery
after Photobleaching. Fluorescent recovery after photobleaching
(FRAP) was conducted on an inverted Eclipse Ti-E microscope
(Nikon Corporation) equipped with a perfect focus system (PFS), a
CFI Apo TIRF 100× oil objective (NA 1.49), a high-pressure mercury
lamp, and an Andor Neo SCC-01322 sCMOS camera (Andor
Technology). Lipid membranes were formed on PVDF thin films,
supported on a glass microscopy slide (0.13−0.16 mm thickness) and
in custom-made ∼100 μL polydimethylsiloxane wells by incubating
LiDo solution mixed with L-α-phosphatidylethanolamine-N-lissamine
rhodamine B sulfonyl (Rh-PE) at a Rh-PE to lecithin ratio of 1:100. A
rhodamine filter set (TRITC, Semrock) was used for visualizing the
lipid membrane. After ∼10 min, the lipid membrane was rinsed and
replaced with lipolysis buffer (50 μL, 200 mM) for a total of five
washes to ensure that any unbound LiDo was removed. Validation of
the lipid membrane was determined by FRAP in epifluorescence
mode, where the Rh-PE lipids were bleached with a Kr−Ar mixed gas
ion laser (Stabilite 2018, Spectra-Physics Lasers, Mountain View, CA)
at a wavelength of 531 nm. The diffusivity of Rh-PE within the
membrane was determined using custom analysis software in
MATLAB (MathWorks) by determining the rate of recovery of the
bleached hole (as described by Jönsson et al.41). The thickness of the
supported lipid membrane was determined by quantifying the
distance between the glass-PVDF thin film interface and the
membrane−buffer interface.
The effect of emulsified SEDDS on membrane integrity was
investigated by incubating the PVDF-supported membrane with each
formulation at a SEDDS concentration of 3.0% (wt/vol), followed by
FRAP analysis. Lipolysis was then initiated by adding a solution of
porcine lipase extract (5 μL, 1000 TBU/mL) and FRAP analysis was
performed at various time points throughout the 60 min digestion
period to determine changes in membrane diffusivity.
Drug Permeation into the Supported Membrane Using
TIRF-M. The effect of emulsified SEDDS under digesting conditions
on the permeation of two model drugs across the adsorbed LiDo
membrane was investigated by encapsulating FEL and LY within each
formulation at a concentration of 0.5 wt %. FEL and LY partitioning,
from the aqueous phase to being enclosed in the lipid membrane, was
visualized over the 60 min digestion period with a DAPI and CFP
filter set (Semrock), respectively. Focus was set at the glass-PVDF
interface to ensure that total internal reflection occurred at the
deepest point of the lipid membrane. The fluorescence intensity
associated with drug permeation was normalized relative to the
fluorescence intensity of the drug at the surface in the absence of an
adsorbed membrane (i.e., drug that is freely available to adsorb at the
surface).
Data Analysis. Statistical analysis was performed in GraphPad
Prism 9 (GraphPad Software, USA) using one-way ANOVA, followed
by a Tukey’s multiple comparison analysis test, to compare differences
for more than two groups. P-values < 0.05 were considered
statistically significant. Area under the curve (AUC) was calculated
with a Python (version 3.6.5) script by fitting data to Akima splines
using scipy.interpolate.Akima1DInterpolator and integrated using
scipy.integrate.IntegrateQuad (SciPy version 1.1.0).
■ RESULTS AND DISCUSSION
FEL Solubility in the Drug-Delivery Systems. FEL was
categorized as freely soluble in the non-ionic surfactants
Tween 85 and Kolliphor RH40 and sparingly soluble in the
triglyceride-based solvents MIGLYOL 812 N and olive oil, see
Table 2. The calculated solubility of FEL in the F3 SEDDS was
21% higher than the experimental solubility (absolute
difference: 1.5%), indicating a slight but significant over-
estimation when using the prediction. Based on these data, the
saturation levels of SEDDS loaded with 22 mg/g FEL were 23,
30, and 15% (±0.3%) for F2, F3, and F4, respectively.
The solubility data of FEL corroborate those found by
Alskar̈ et al.,33 in which FEL solubility was determined for
similar triglyceride compositions (soybean oil and CAPTEX
355). Relative difference in observed solubility (mg/g) of FEL
in MIGLYOL 812 N and olive oil was less than 10% of that in
CAPTEX 355 and in soybean oil, respectively (Table 2). The
absolute difference was less than 0.1% by molar fraction, which
was expected because MIGLYOL 812 N and olive oil contain
the same components as CAPTEX 355 and soybean oil,
respectively, albeit at slightly different fractions. According to
the manufacturer’s information, CAPTEX 355 can contain a
higher proportion tricaprylin than MIGLYOL 812 N, but for
the most part, the specifications overlap. Olive oil and soybean
oil mainly differ in the proportion of monounsaturated to
polyunsaturated C18 triglycerides.42,43 It could also be
predicted that digestion of SEDDS F2−F3 would increase
solubility because of the reported higher solubility in mixtures
of di- and monoglycerides compared to triglycerides of the
same chain length.33 Note that this prediction is contingent on
the assumption that solubility in the SEDDS components
reflects solubility in the emulsion. For the most similar
surfactants, the discrepancies were far larger with Tween 85
and Kolliphor RH40, with relative differences in FEL solubility
(mg/g) of 177 and 41%, compared to Tween 80 and Kolliphor












Tween 85 125 ± 1.2 0.598 ± 0.006 0.406 ± 0.006 18
Kolliphor RH40 177 ± 8.7 1.211 ± 0.060 0.594 ± 0.057 12
Olive oil 10.5 ± 0.3 0.023 ± 0.001 0.023 ± 0.001
F1 (MCT)b 27.4 ± 0.5 0.036 ± 0.001 0.036 ± 0.001 80
F2 (s + MCT)b 96.4 ± 1.3 23d
F3 (s + LCT)b 74.3 ± 0.8 0.312 ± 0.003 0.252 ± 0.003 89.6 ± 1.4 30
F4 (s)b 142 ± 2.3 15d
Tween 80 45.2±4.36c 0.154±0.015 0.139±0.015 49
Kolliphor EL 125±6.23c 0.782±0.039 0.472±0.038 18
Soybean oil 9.59±0.67c 0.218±0.002 0.022±0.002
Captex 355 26.4±1.75c 0.035±0.002 0.034±0.002 83
aSolubility for additional SEDDS components (in italics), similar to those included in this study, are included for comparison. Values expressed as
mean ± standard deviation (n = 3). bF1 is composed of 100% MIGLYOL 812 N, which is a component of F2. See Table 1 for specifications of the
solvents/drug-delivery systems F1−F4, which include surfactants (s), medium-chain triglycerides (MCT), or long-chain triglycerides (LCT).
cFrom Alskar̈ et al., ref 33. dFrom calculated solubility.
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EL, respectively (Table 2). By molar fraction, the absolute
difference was 27 and 12%, respectively. The differing
solubility in the surfactants could be interpreted to be a result
of lipophilicity differences: the castor oil-derived surfactant
studied by Alskar̈ et al. (Kolliphor EL) is more lipophilic than
the one studied here (Kolliphor RH40). Furthermore, FEL was
shown to be more soluble in mixed di- and monoglyceride
compositions than triglyceride compositions.33 However, the
polyethoxylated sorbitan ester surfactants break this pattern, as
FEL had lower solubility in Tween 80 than in Tween 85, but
the former could be considered less lipophilic with only one
oleate moiety compared to three for the latter.
Impact of SEDDS Composition on Drug Flux during
In Vitro Lipolysis-Permeation Studies. The different
SEDDS appeared to have a significant impact on both the
fraction dissolved and the mass transfer of FEL across the
artificial membrane. During lipolysis at 37 °C without
absorption sink, the triglyceride SEDDS (F2−F3) appeared
equally capable of keeping FEL solubilized, while the pure
surfactant system F4 had a significantly lower solubilizing
capacity (Table 3). However, when adjusting the fraction
dissolved without absorption sink for the observed membrane
fractions from separate lipolysis-permeation experiments, more
FEL would appear to be in the aqueous solution in the donor
Table 3. Fraction-Dissolved (Fdiss) FEL from In Vitro Lipolysis Experiments and Fraction in Membrane (Fmem) from Lipolysis-
Permeation Experimentsa
Fdiss Fmem Fdiss × (1 − Fmem)
SEDDS 37 °C RT 37 °C RT 37 °C RT
F2 93 ± 15 83 ± 7 19 ± 1 14 ± 0.6 75 ± 12 71 ± 6
F3 87 ± 5 81 ± 7 30 ± 0.8 19 ± 1.2 61 ± 3 66 ± 5
F4 52 ± 9 55 ± 5 3 ± 3.6 12 ± 1 51 ± 9 48 ± 4
aAdjusting Fdiss by the apparent amount not found in the membrane [Fdiss × (1 − Fmem)] indicates the effect of having a membrane present.
Average ± standard deviation over all time points.
Figure 2. Concentration (μM) of FEL over time profiles of FEL loaded in SEDDS F2 (blue ▲), F3 (green ●), and F4 (red ■) at (a,b) 450 rpm/
37 °C, (c,d) no shaking/room temperature. Left panels: Fraction of solubilized FEL (Fdiss) during independent in vitro lipolysis experiments (n =
2), conducted without absorption but adjusted for membrane absorption (Fmem) determined from separate lipolysis-permeation experiments. Open
symbols with colors at −10 and 60 min digestion show Fdiss from lipolysis-permeation experiments (n = 3 technical repeats), where membrane
binding is built into the model. Right panels: Concentration of FEL (μM) in the receiver compartment (n = 3 technical repeats). In (b), SEDDS F1
is shown for different methods of adding the sample: predispersing by vortex mixing (▽), predispersing by high-shear mixing (□), and direct
addition to insert (◇). Shaded areas along the curves show standard deviation. Insets show integrated mass-transfer profiles of FEL over 0−70 min,
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with F2 than with F3−F4 (Figure 2a). The difference for F2 is
significant up until the 50 min mark; thereafter, FEL appeared
to crash out of solution. This sudden decrease in the fraction
dissolved is likely connected to the sharp increase in digestion
observed at the same time (Figure 3a−c). As mentioned
previously, the solubility could be expected to increase with
digestion due to an increased proportion of monoglycerides
and fatty acids, and thus the precipitation event is conspicuous.
Conceivably, this event is related to a reorganization of the
colloidal structure, as the emulsion generated by the F2
SEDDS appeared to crack at the same point, forming two
visually distinct phases of different density and opacity (Figure
S1a,b).
Dynamic light scattering data (DLS) obtained for this
formulation show a significant change in the droplet size
distribution during the digestion of this emulsion (Figure S1a).
The dispersion was initially monomodal, with an increasing
hydrodynamic diameter of droplets from 42 nm prior to
lipolysis up to 65−76 nm during the first 5% of digestion. The
droplet size decreased to 40 nm after 10−15% digestion,
possibly stemming from the generation of vesicles or mixed
micelles from the digested surface of the droplets. At 20%
digestion (∼45 min), the distribution became bimodal as
portion of the emulsion droplets appeared to swell to 257 nm.
This bimodality coincided with the observed decrease in
solubilized FEL and increase in the rate of digestion. Finally, at
30−50% digestion (∼50−55 min), the emulsion seemed to
crack, appearing turbid with stirring and phase separating at
rest (Figure S1b). At this point, the larger droplets appeared to
coalesce and give rise to a trimodal distribution with droplets
Figure 3. Release of free fatty acids (FFA) from SEDDS F2 (s + MCT), F3 (s + LCT), and F4 (s) when digested by porcine lipase (a−c) at 37 °C,
or (d−f) at room temperature in lipolysis experiments without absorption. The total released FFA (top row) was calculated from the ionized FFA
directly measured by titration (middle row) by adjusting for the fraction unionized estimated by titration to pH 9 after 60 min to fully ionize FFA,
and subtracting the blank digestion medium (FaSSIF). Based on the number of FFA moieties present, an approximate extent of digestion (bottom
row) was calculated. Shaded areas represent the standard deviation.
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from 40 nm to several μm. No significant change in appearance
or droplet size was observed for F3, with an average size of 52
± 11 nm (range 37−70 nm, average PDI 12% ± 4.4%).
The emulsions generated by F2 and F4 contributed to
higher mass transfers over the membrane than F3 in IVLP
experiments (Figure 2b). Flux could not be calculated
explicitly due the non-linearity of mass transfer over time,
but a measure of flux across the membrane was obtained by
integrating these profiles as AUC. From the AUC, it was clear
that F3 was significantly less able to promote flux of FEL. In
addition to this, several distinct permeation profiles were
generated when FEL was loaded in pure triglycerides (F1),
depending on the method of dispersion. In the indirect
dispersion method employed for all formulations, F1 produced
a significantly lower flux of FEL across the membrane. This
reduced flux was probably due to the tendency for the
emulsions to cream, leading to a much lower surface area for
the lipid phase. A lower surface area will also reduce the rate of
lipolysis, as pancreatic lipase is activated at the interface of lipid
and aqueous phases.44 The reduced droplet surface area seems
to affect the absorption rate more than the transfer process, an
idea that is supported by the even lower flux when F1 was
added to the donor medium directly in the insert. When high-
shear mixing was used to disperse F1, the flux of FEL
significantly increased, but did not reach that of the surfactant-
containing F2−F4 SEDDS.
The correlation between solubilized FEL in the donor (IVL
experiments) and the flux across the membrane (IVLP
experiments) was generally poor, as expected based on
previous studies.17,19,20 Because the concentrations of FEL in
the continuous phase are unknown, it is difficult to draw
conclusions from observed concentration profiles in the donor
of either assay format. However, the end-of-experiment
solubilized fraction in IVLP experiments corresponded better
to receiver AUCs from the same experiments, than the donor
solubilization profiles from IVL experiments did. Additionally,
the IVLP flux appeared to be negatively correlated with the
emulsion droplet size observed in IVL experiments. A recent
study by Kabedev et al. explored the interaction of the
lipophilic drug substance danazol with a phospholipid
bilayer.45 Their results indicated that mixed-micelles composed
of sodium taurocholate and 1,2-dilinoleoyl-sn-glycero-3-
phosphatidylcholine (DLiPC) can act as shuttles to deliver
the payload directly to the membrane interface, or can also fuse
with the membrane. While these interactions may be less
important than absorption of drug from the continuous phase,
they cannot be accounted for in vitro without the presence of a
biomimetic membrane. These results reported here, therefore,
serve to reinforce the notion that an absorption compartment
is useful when studying digestible colloidal systems.
Under benchtop conditions (no shaking, room temper-
ature), the SEDDS appeared to have different effects on the
mass transfer of FEL across the membrane than they did under
conditions more closely resembling physiological conditions.
The observed solubilization capacity in IVL experiments
(Table 3) did not strongly differ despite the reduced digestion
(Figure 3d−f). However, after adjusting for membrane-bound
fraction from the IVLP experiments, the fraction dissolved with
F2 and F3 in IVL experiments was more similar at room
temperature (Figure 2c) than at 37 °C (Figure 2a) due to the
lower amounts of FEL in the membrane at room temperature,
and there were lower relative differences between membrane
fractions (Table 3). Despite this, F3 and F4 induced
significantly higher mass transfer of FEL across the membrane
than F2 at room temperature (Figure 2d).
The absence of increased digestion rate and reduced fraction
dissolved for F2 at room temperature in IVL experiments
could be due to a lack of colloidal rearrangement within the 60
min timeframe, as indicated by DLS, which showed no
difference in the droplet size (46 ± 1.4 nm, n = 22) from
dispersion to end of experiment for the F2 emulsion. However,
the IVLP flux of FEL in F2 increased toward the end of the
experiment, more than F3−F4. IVL experiments indicate that
the rate of digestion decreased within the first 15 min (0−1%
digestion), became constant between 15 and 50 min (1−3%
digestion), and then increased toward the end for the F2
emulsion, while continuing to decrease for F3−F4. It would
thus appear that an increasing rate of digestion is beneficial for
the flux of FEL. In the corresponding 37 °C experiment, a
similar relationship between the IVLP flux and IVL digestion
rate could be seen initially, but a decrease in flux preceded the
observed strong increase in the digestion rate between 15 and
50% digestion. Thus, increasing digestion rates appeared
beneficial for the flux of FEL in the medium-chain SEDDS
(F2) initially, but detrimental at more advanced stages of
digestion. Furthermore, colloidal rearrangement appeared to
be an important factor influencing the flux of FEL when loaded
in the F2 SEDDS. It should be noted that in the small
intestine, lipid digestion products (i.e., fatty acids and
monoglycerides) are efficiently absorbed and removed from
the system.46 In vitro, these products remain in the system,
with only a minor fraction of fatty acids being bound by
calcium, and thus the effects of intestinal digestion on colloidal
rearrangement may be inaccurately portrayed. It is unlikely that
the observed cracking of the emulsion from F2 SEDDS would
occur in the small intestine, as digestion products would be
continuously removed, thus maintaining the increased rate of
absorption for longer.
A higher activity of lipase (500−1000 TBU/mL) is typically
used for in vitro lipolysis assays.47 When it comes to
permeation assays involving SEDDS, the activity has much
more commonly been 0, with the lipase inhibited prior to
contact with absorptive membranes or simply not included.
Only a few studies have shown simultaneous lipolysis and
absorption in vitro. Two of those were conducted with cell
monolayers as absorption barriers and digestion by 12.5 mg/
mL of Novozym 435,6,17 corresponding to an activity of 50
TBU/mL. More recently, cell-free assays simultaneously
combining lipolysis and absorption have been published: two
lipolysis-permeation assays,19,20 and one biphasic lipolysis
assay.48 Porcine pancreatin was used in these studies, with an
activity roughly corresponding to 800−1300 TBU/mL and
thus considerable higher than in our work. To put these
numbers in context, the lipase activity of the human fasted
intestine has been reported to be around 500−600 TBU/mL.49
In these cell-free assays, good correlations to in vivo plasma
AUCs were reported but accurate ranking of the formulations
was not achieved with the IVLP assays.19 Furthermore, ranking
and correlation was poorer when using data from the initial 30
min of in vitro assay as compared to 6 h. At these high
activities, the digestion is essentially completed within the first
15−30 min. Thus, it might be better to slow the lipolysis down
in vitro when the rate of absorption is much lower than in vivo.
With the LiDo artificial membrane, the risk of decreased
membrane integrity at higher levels of lipase activity has not
been fully explored. In our previous study, we used 660 TBU/
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mL of porcine pancreatin for digestion of these same
formulations. Flux of fenofibrate was observed to increase
sharply in some cases between 30−60 min of digestion of the
F2 and F3 SEDDS. No increase in the flux of LY was detected,
but the increased flux of more permeable substances might
have come from reduced membrane integrity. In that study,
like the aforementioned other studies, we were not able to
show a good agreement between initial 30 min AUCs and in
vivo plasma AUCs. We, therefore, chose a lower activity of 100
TBU/mL in the current study, to reduce the risk of membrane
integrity loss as well as possibly leading to better agreement
between in vitro and in vivo absorption in this type of assay.
Investigating Colloidal Interactions with Supported
Membranes Using QCM-D. We hypothesized that the
colloidal rearrangement of lipid structures during lipolysis
was the driving force altering the structure and permeability of
the adsorbed membrane and thereby contributing to
formulation-dependent changes in drug flux. To investigate
this idea, the interactions between each SEDDS with
supported membranes adsorbed on nanostructured PVDF
thin films (Figure S5) were investigated through changes in
frequency ( f) and dissipation energy (D) using QCM-D
(Figure 4). Decreased f always corresponds to an increase in
the mass or density of the adsorbed layer on the sensor, and
vice versa, whereas changes in D that are not matched by
corresponding inverse changes in f indicate a change in the
viscoelasticity of the adsorbed layer. For example, if D
increases independently of f, this indicates reduced rigidity
(increased viscoelasticity) and possible structural changes.
However, if such an increase in D is matched by a decrease in f,
this would only indicate increased mass and no change in the
viscoelasticity. Alternatively, if f increases together with
increasing D, this would indicate a decrease in mass and
reduced rigidity (increased viscoelasticity).
In all experiments, performed in independent triplicates,
thick multilayer adsorption of LiDo onto the PVDF surface
was identified after 10−20 min by a rapid and significant
decrease in f, coupled with an increase in D (stage II). After 20
min, exposure of the membrane to the emulsified SEDDS in
FaSSIF medium (stage III) triggered an increase in f and an
increase in D for all SEDDS, except for F1 (decrease in D).
This indicates a reduction of mass on the sensor, but also
reduced rigidity (increased viscoelasticity) of the adsorbed
film. This pattern may be attributed to the surfactant nature of
the phospholipids and bile salts within the FaSSIF media that
are capable of penetrating and removing amphiphilic
membrane components through the formation of micelles
and other colloidal structures,45 subsequently decreasing the
mass and increasing the viscoelasticity of the adsorbed
membrane.
Lipolysis was initiated after 10 min of flushing the QCM-D
cell with emulsion, to allow for equilibrium with the membrane
Figure 4. LiDo on the PVDF-treated sensor chip, QCM-D profiles of digestion of drug-delivery systems (a) F1 (MCT), (b) F2 (s + MCT), (c) F3
(s + LCT), and (d) F4 (s). Stages shown in each graph: (I) QCM-D sensor is flushed with n-dodecane → (II) multilayer adsorption of LiDo
solution onto PVDF surface → (III) emulsified SEDDS in FaSSIF media → (IV) lipolysis was initiated through addition of porcine lipase to the
dispersion reservoir. The orange solid lines show changes in frequency (Hz, left y-axis) over time, and dashed blue lines show changes in dissipation
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to be reached. Lipase was added to the reservoir and the
experimental setup was shifted to closed-loop QCM-D,
allowing continuous flow of the digesting SEDDS medium to
the sensor for 60 min (stage IV). Initially, this addition was
reflected in only minor changes to f and D for F2, F3, and F4.
In contrast, a sharp decrease in f and an increase in D were
observed for F1 within the first minutes of lipolysis (Figure
4d), which we hypothesize was a result of lipolysis products
increasing the overall emulsification of the formulation within
the lipolysis vessel. F1 is composed of lipids in the absence of
surfactants, and therefore, this formulation emulsifies poorly
under non-digesting conditions because the concentration of
phospholipids and bile salts in FaSSIF is not sufficient to
prevent the separation between the oil and aqueous phases.
However, once digestion begins, amphiphilic digestion
products (i.e., fatty acids, monoglycerides, and diglycerides)
are formed, which aid in emulsifying the lipid components
through stabilizing the lipid-in-water interface.50 This process
was expected to increase the exposure of the lipid component
to the adsorbed membrane within the QCM-D cell, thus
increasing the interaction (i.e., adsorption) of SEDDS
components with the lipid membrane, and indeed, this pattern
was observed as evidenced by changes in f and D. For the
remaining formulations, which were well-emulsified due to the
presence of surfactants, the immediate change in adsorbed
mass and viscoelasticity was not significant upon addition of
lipase, because each of these formulations were already well
exposed to the membrane.
However, changes in adsorption behavior or membrane
structure were evident for F2 after ∼30 min of lipolysis (Figure
4a), through observed dynamic changes in f and D. The
synchronicity of f and D indicate deposition and removal of
mass, but no structural changes in the adsorbed film at this
stage. Such changes were not observed for F3 within the 60
min lipolysis period (Figure 4b), but could be seen after 90
min lipolysis (Figure S2). These findings suggest that the
adsorption or structural changes observed on the lipid
membrane are dependent on lipolysis kinetics, which for F2
and F3 are controlled by changes in the lipid chain length, with
shorter-chain lipids (F2) being digested more rapidly. Lipolysis
data (Figure 3) support this hypothesis because fatty acid
titration kinetics of F2 underwent a significant change in a
timeframe similar (t = 45 min) to the adsorption or structural
changes observed in QCM-D studies. Furthermore, the steady
f and D observed for the nondigestible F4 formulation (Figure
4c), along with the significant changes to f and D observed
after 50 min lipolysis for the lipid-only F1 formulation (Figure
4d), indicate that lipolysis triggers changes to adsorption
behavior or membrane structure.
The described events were broadly reproducible in
independent replicates (n = 3). Coupling these findings with
the understanding that colloidal self-assembly of lipolysis
products into various liquid crystalline structures is controlled
by digestion kinetics,16 we can hypothesize that interactions
between digestible SEDDS and the adsorbed membrane are
mediated through colloidal rearrangements of the lipid
components. The exact mechanism of this interaction is not
clear, but it is expected that colloidal rearrangement alters the
exchange of lipid monomers between the adsorbed membrane
and the lipid colloids solubilized within the aqueous media.51
To assess whether the dynamic changes in f and D were
dependent on the presence of the supported membrane,
QCM-D studies were performed in the absence of LiDo,
meaning that digesting SEDDS were exposed to the bare
PVDF thin films (Figure S3). Importantly, adsorption patterns
revealed similar changes in f and D after ∼50 and ∼60 min for
F2 and F3, respectively. While the timeframes of these f and D
changes do not directly align with changes in the presence of a
lipid membrane, these observations support the hypothesis
that colloidal rearrangement triggered by lipolysis leads to
changes in the adsorption of SEDDS onto surfaces, including
both the bare (hydrophobic) PVDF surface and the adsorbed
LiDo membrane.
Impact of SEDDS on the Lateral Diffusivity of
Supported Membranes Using FRAP. FRAP analysis was
used to quantify the lateral mobility of adsorbed LiDo
membranes when subjected to various SEDDS under digesting
conditions, to ascertain whether adsorption of SEDDS
components (digested and non-digested) affected lipid
diffusivity. First, the LiDo membranes were incubated with a
small portion of a fluorescent probe (rhodamine B-labeled
DOPE), and then the rate of recovery of a photobleached area
was monitored (Figure S4). Reduced lipid mobility indicates a
ruptured, non-continuous membrane,41 and therefore lipid
diffusivity is a direct indicator of membrane integrity. FRAP
analysis revealed that the adsorbed LiDo membrane remained
intact when exposed to digestible SEDDS of all compositions
over the course of a 60 min lipolysis period, as evidenced by
recovery of the photobleached area.
Previous studies have suggested that small changes to the
supported membrane structure and composition can trigger
alterations to lateral diffusivity.52,53 Here, FRAP analysis of the
Figure 5. Calculated lateral diffusivity (xy-plane) of rhodamine B-labeled DOPE in LiDo membranes, as observed with TIRF microscopy and
FRAP. Data are shown as mean and standard deviation (shaded area) of independent replicates (n = 3). (a) Diffusivity of the marker with blank
digestion medium (FaSSIF) under lipolysis. (b) Different formulations dispersed in digestion medium under lipolysis.
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adsorbed membrane exposed to FaSSIF under digesting
conditions, in the absence of any SEDDS, revealed fluctuating
diffusivities of 2−8 μm2/s after 30 min lipolysis (Figure 5a).
This finding indicates that membrane exposure to the colloidal
systems associated with FaSSIF and hydrolytic lipase enzymes
is enough to cause changes in lipid arrangement within the
adsorbed membrane. These rearrangements are probably due
to the dynamic equilibrium that exists between lipids adsorbed
to the PVDF surface and lipids within the bulk aqueous
environment, whereby continuous exchange is expected. This
dynamic equilibrium is expected to be dependent on lipolysis
kinetics and colloidal self-assembly because changes in the
composition and structure of lipid colloids alter the expulsion
dynamics of individual lipid monomers.51
Exposure of the adsorbed membrane to the non-digestible
F4 SEDDS revealed negligible fluctuations in lateral diffusivity
over the 60 min lipolysis period (Figure 5b), suggesting
reduced interaction compared to FaSSIF alone. The presence
of surfactants appears to attenuate the effect of FaSSIF
components on lateral diffusivity. In contrast, exposing the
adsorbed membrane to F2 and F3 under digestion conditions
led to spikes in lateral diffusivity at 30 and 45 min, respectively.
These findings correlate well with QCM-D observations, where
changes in f and D were shown to be dependent on lipolysis
kinetics for F2 and F3. In summary, FRAP analysis in
conjunction with QCM-D findings indicates that F4 has little
impact on the membrane structure and composition, while F2
and F3 appear to affect the membrane depending on lipid
digestion kinetics and subsequent rearrangement of lipid
colloids. It should be noted that the FRAP analysis was run at
room temperature, which reduced the rate of digestion.
Impact of SEDDS on Drug Permeation Across the
Adsorbed Membrane Using TIRF-M. TIRF-M presents
unique opportunities for monitoring time-dependent drug
partitioning and permeation across supported membranes
because the evanescent wave created by light reflecting at the
interface between a material with a higher index of refraction
(i.e., the glass/silica substrate) and a material of lower index of
refraction (i.e., PVDF thin film) decays exponentially into the
material of lower refractive index.54 This means that it is
possible to limit the depth of penetration of the evanescent
wave to ∼100−200 nm by increasing the critical angle required
for total internal reflection. This approach was previously used
to monitor FEL permeation across a lipid bilayer supported by
a ∼500 nm thick mesoporous silica thin film.55 By restricting
total internal reflection to within the pores, it was possible to
observe the fluorescence associated with only the FEL that
diffused across the supported membrane. A similar approach
was used in this study, with the LiDo membrane adsorbed
onto a porous PVDF support. In the previous study, the pores
were ∼7 nm in diameter, allowing the lipid bilayer to be
supported above the porous thin film; in this study, the pores
of the PVDF support were 0.84 ± 0.1 μm, which meant that
the LiDo membrane adsorbed throughout the porous network.
Subsequently, it was not possible to monitor drug permeation
across the membrane, only drug partitioning within the
membrane. However, by confining total internal reflection to
the glass-PVDF surface, it was possible to restrict the
evanescent wave illumination to a ∼100−200 nm thick
subsection within the deepest point of the membrane (Figure
6a). Because the membrane was at least 16 μm thick
(calculated by changing the z-position between the glass-
PVDF thin film interface and the membrane−buffer interface),
it can be assumed that any fluorescence detected within the
subsection closest to the glass-PVDF interface was available to
diffuse across the lipid membrane.
The permeation of poorly permeable LY was first analyzed
to serve as a negative control to demonstrate the integrity of
the membrane when exposed to each SEDDS under digesting
conditions. Importantly, the fluorescence intensity associated
with LY diffusion to the glass-PVDF interface was low for all
formulations (Figure 6b), indicating that the membrane
remained intact when exposed to SEDDS under digesting
conditions. F2 had the greatest normalized fluorescence
intensity (0.069 ± 0.005 a.u.) of LY diffusion, roughly 7−12
times more intense than the fluorescence of F3 and F4. In sum,
it can be concluded that F2 interacted with the membrane to
the greatest extent, and thus has a marginally higher potential
to affect membrane integrity.
A time-dependent increase in fluorescence intensity was
observed for FEL diffusion across the membrane for all
SEDDS, with F3 and F4 reaching normalized fluorescent
intensities indicating drug diffusion of ∼0.6 a.u. after 60 min
lipolysis (Figure 6b). In contrast, the normalized fluorescent
intensity of FEL diffusion for F2 was only 0.41 ± 0.03 a.u. This
result poorly correlates with the bulk lipolysis-permeation
Figure 6. (a) Schematic of the TIRF experiment with the illuminated field represented by the red lines. Legend: SEDDS (orange circles), lipase
(green), drug (black dots), membrane (yellow), and filter support (gray). (b) TIRF-M data of normalized mean fluorescence intensity of LY (open
symbols) and FEL (closed symbols) at the glass/PVDF interface, basal side of LiDo membranes. FEL was loaded in different SEDDS: F2 (blue ▲),
F3 (green ●), and F4 (red ■). Shaded areas show the standard deviation.
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studies performed at 37 °C with stirring. However, strong
correlations were obtained between the normalized fluores-
cence intensity data and bulk lipolysis-permeation studies
performed at room temperature without stirring, and so data
obtained under static conditions yielded similar results. This
result highlights a key limitation of utilizing TIRF-M for
analyzing drug partitioning and permeation, and shows that
these studies need to be supported with corresponding bulk
permeation studies under equivalent experimental conditions.
No clear spikes in FEL diffusion were observed, which suggests
that the changes in membrane structure as discerned by FRAP
analysis (under equivalent experimental conditions) did not
lead to changes in drug partitioning and permeation. Most
importantly, the complementary nature of QCM-D, FRAP, and
TIRF-M strongly indicates that LiDo membranes adsorbed
onto nanostructured PVDF substrates maintain their integrity
when exposed to the digesting conditions of lipid-based
formulations. This result highlights the applicability of these
membranes for assessing drug permeation during lipolysis.
■ CONCLUSIONS
The results from this study reinforce the importance of lipid
digestion during in vitro drug absorption assays of SEDDS, as
lipolysis will have a significant impact on the observed relative
performances. A correlation between FEL flux and lipid
digestion kinetics was observed, more so than with a
solubilized donor concentration. However, neither drug
solubilization nor formulation digestion profiles are likely to
be good predictors of intestinal drug absorption from SEDDS;
rather, these processes need to be studied in concert. QCM-D
and TIRF-M studies revealed differences in formulation-
mediated interactions with the membrane, which were
amplified by lipid digestion, but importantly, these experiments
demonstrated the ability of the adsorbed membrane to remain
intact under digesting conditions. The microscopy-based
results should be interpreted with caution because the lower
temperature restricted the extent of digestion during the
experimental timeframe. However, taken together, all results
from this study suggest that the LiDo-based artificial
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Evaluation of Lipid-Based Formulations for Oral Delivery of
Apomorphine and Its Diester Prodrugs. Int. J. Pharm. 2016, 513,
211−217.
(6) Alskär, L. C.; Parrow, A.; Keemink, J.; Johansson, P.;
Abrahamsson, B.; Bergström, C. A. S. Effect of Lipids on Absorption
of Carvedilol in Dogs: Is Coadministration of Lipids as Efficient as a
Lipid-Based Formulation? J. Controlled Release 2019, 304, 90−100.
(7) Cherniakov, I.; Izgelov, D.; Barasch, D.; Davidson, E.; Domb, A.
J.; Hoffman, A. Piperine-pro-Nanolipospheres as a Novel Oral
Delivery System of Cannabinoids: Pharmacokinetic Evaluation in
Healthy Volunteers in Comparison to Buccal Spray Administration. J.
Controlled Release 2017, 266, 1−7.
(8) Cherniakov, I.; Izgelov, D.; Domb, A. J.; Hoffman, A. The Effect
of Pro NanoLipospheres (PNL) Formulation Containing Natural
Absorption Enhancers on the Oral Bioavailability of Delta-9-
Tetrahydrocannabinol (THC) and Cannabidiol (CBD) in a Rat
Model. Eur. J. Pharm. Sci. 2017, 109, 21−30.
Langmuir pubs.acs.org/Langmuir Article
https://doi.org/10.1021/acs.langmuir.1c01689
Langmuir 2021, 37, 10200−10213
10211
(9) Kamboj, S.; Sethi, S.; Rana, V. Lipid Based Delivery of Efavirenz:
An Answer to Its Erratic Absorption and Food Effect. Eur. J. Pharm.
Sci. 2018, 123, 199−216.
(10) Kazi, M.; Al-Swairi, M.; Ahmad, A.; Raish, M.; Alanazi, F. K.;
Badran, M. M.; Khan, A. A.; Alanazi, A. M.; Hussain, M. D. Evaluation
of Self-Nanoemulsifying Drug Delivery Systems (SNEDDS) for
Poorly Water-Soluble Talinolol: Preparation, in Vitro and in Vivo
Assessment. Front. Pharmacol. 2019, 10, 459.
(11) Koehl, N. J.; Holm, R.; Kuentz, M.; Griffin, B. T. Chase Dosing
of Lipid Formulations to Enhance Oral Bioavailability of Nilotinib in
Rats. Pharm. Res. 2020, 37, 124.
(12) Koehl, N. J.; Henze, L. J.; Kuentz, M.; Holm, R.; Griffin, B. T.
Supersaturated Lipid-Based Formulations to Enhance the Oral
Bioavailability of Venetoclax. Pharmaceutics 2020, 12, 564.
(13) Yen, C.-C.; Chang, C.-W.; Hsu, M.-C.; Wu, Y.-T. Self-
Nanoemulsifying Drug Delivery System for Resveratrol: Enhanced
Oral Bioavailability and Reduced Physical Fatigue in Rats. Int. J. Mol.
Sci. 2017, 18, 1853.
(14) Mishra, V.; Nayak, P.; Yadav, N.; Singh, M.; Tambuwala, M.
M.; Aljabali, A. A. A. Orally Administered Self-Emulsifying Drug
Delivery System in Disease Management: Advancement and Patents.
Expet Opin. Drug Deliv. 2021, 18, 315−332.
(15) Williams, H. D.; Sassene, P.; Kleberg, K.; Bakala-N’Goma, J.-C.;
Calderone, M.; Jannin, V.; Igonin, A.; Partheil, A.; Marchaud, D.; Jule,
E.; Vertommen, J.; Maio, M.; Blundell, R.; Benameur, H.; Carrier̀e, F.;
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